Toxins and drug discovery

Harvey, Alan L. (2014) Toxins and drug discovery. Toxicon, 92. pp. 193-200. ISSN 1879-3150

Preview

PDF (Harvey-Toxicon-2014-Toxins-and-drug-discovery)
Harvey_Toxicon_2014_Toxins_and_drug_discovery.pdf
Final Published Version
License:

Download (397kB)| Preview

Official URL: https://doi.org/10.1016/j.toxicon.2014.10.020

Abstract

Components from venoms have stimulated many drug discovery projects, with some notable successes. These are briefly reviewed, from captopril to ziconotide. However, there have been many more disappointments on the road from toxin discovery to approval of a new medicine. Drug discovery and development is an inherently risky business, and the main causes of failure during development programmes are outlined in order to highlight steps that might be taken to increase the chances of success with toxin-based drug discovery. These include having a clear focus on unmet therapeutic needs, concentrating on targets that are well-validated in terms of their relevance to the disease in question, making use of phenotypic screening rather than molecular-based assays, and working with development partners with the resources required for the long and expensive development process.

Citations and altmetrics

Item metadata

Item type:	Article
ID code:	51797
Dates:	Date Event 15 December 2014 Published 29 October 2014 Published Online 15 October 2014 Accepted
Keywords:	conus venoms, drug development venoms to drugs, drug discovery, phenotypic screening, snake venoms, Pharmacy and materia medica, Toxicology
Subjects:	Medicine > Pharmacy and materia medica
Department:	University of Strathclyde > University of Strathclyde Faculty of Science > Strathclyde Institute of Pharmacy and Biomedical Sciences Faculty of Science
Depositing user:	Pure Administrator
Date deposited:	19 Feb 2015 14:47
Last modified:	01 Apr 2021 00:30
Related URLs:	Scopus publication Journal or Publication
URI:	https://strathprints.strath.ac.uk/id/eprint/51797

Export

CORE (COnnecting REpositories)